AstraZeneca seeks U.S. FDA approval for lung cancer treatment

AstraZeneca and HUTCHMED filed for US FDA approval of the ORPATHYS-TAGRISSO combination for advanced lung cancer. The treatment showed improved survival rates over chemotherapy. ORPATHYS is already approved in China. (Reuters)

Summit Therapeutics (SMMT) announced a US$2B investment from AstraZeneca (AZN) via convertible preferred shares at US$18.36 per common-share equivalent, an 18.6% premium. The deal, expected to close by Oct. 2, will fund cancer drug development, including ivonescimab. AstraZeneca will own about 12% of Summit's outstanding common shares post-investment.

HUTCHMED and AstraZeneca submitted a US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer. The Phase III SAFFRON trial showed significant improvements in progression-free and overall survival over chemotherapy. FDA approval is pending. (HCM, AZN)

Summit Therapeutics (SMMT) shares surged 19% after hours as AstraZeneca (AZN) agreed to invest $2 billion in convertible preferred stock, valued at $18.36 per share. The deal, expected to close this week, gives AZN a 12% stake. Summit will use funds for clinical trials, addressing its cash concerns. The companies will collaborate on cancer drug trials, with AZN sponsoring and splitting costs. Summit's cash reserves were $690.7M as of Q2, insufficient for a full year of operations.

AstraZeneca (AZN) received FDA Priority Review for IMFINZI in combination with EV to treat bladder cancer, with a decision expected in Q4 2026. The company reported 6% revenue growth in H1 2026, driven by double-digit expansion in Oncology and Rare Disease. AstraZeneca faces pressure from mature assets but aims to offset this with its expanding oncology portfolio.

AstraZeneca plans to invest $2 billion in Summit Therapeutics, causing a jump in Summit's shares. The investment highlights a strategic partnership between the two companies, which could impact Summit's future growth and financial performance.